See All Slides - tctmd.com

Slides

Presentation TCT 2012

SDF-1: Circumventing the Application of Cell Products in Heart Failure

Presenter: Warren Sherman

October 22, 2012

Presentation TCT 2012

Perivascular MAPCs: Long Term Follow Up and Next Steps

Presenter: Warren Sherman

October 22, 2012

Presentation TCT 2012

The Evolution of a Stem-cell Based Strategy: From Enhanced Collateral Function to Wound Healing

Presenter: Stephen Epstein

October 22, 2012

Presentation TCT 2012

Case Presentation (with Discussion): Non-Left Main True Bifurcation Technique

Presenter: John Lasala

October 22, 2012

Presentation TCT 2012

Simplifying PCI of Left Main Trifurcation Disease

Presenter: Antonio Colombo

October 22, 2012

Presentation TCT 2012

STOP-IC: A Prospective, Randomized Trial of Cilostazol after Endovascular Treatment of Femoropopliteal Lesions

Presenter: Hiroyoshi Yokoi

October 22, 2012

Presentation TCT 2012

The PREVAIL XT (TF and TA) Registries

Presenter: Stefan Sack

October 22, 2012

Presentation TCT 2012

DES vs. BMS in STEMI: Why Is This Such a Difficult Decision?

Presenter: Giuseppe De Luca

October 22, 2012

Presentation TCT 2012

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Presenter: Philip Green

October 22, 2012

Presentation TCT 2012

Case Presentation with Discussion(8)

Presenter: Ariel Duran

October 22, 2012

Advertisement

Slides

SDF-1: Circumventing the Application of Cell Products in Heart Failure

Perivascular MAPCs: Long Term Follow Up and Next Steps

The Evolution of a Stem-cell Based Strategy: From Enhanced Collateral Function to Wound Healing

Case Presentation (with Discussion): Non-Left Main True Bifurcation Technique

Simplifying PCI of Left Main Trifurcation Disease

STOP-IC: A Prospective, Randomized Trial of Cilostazol after Endovascular Treatment of Femoropopliteal Lesions

The PREVAIL XT (TF and TA) Registries

DES vs. BMS in STEMI: Why Is This Such a Difficult Decision?

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Case Presentation with Discussion(8)

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content